Targeting PAK1

Galina Semenova, Jonathan Chernoff

Research output: Contribution to journalReview articlepeer-review

58 Scopus citations

Abstract

p21-Activated kinase 1 (PAK1) has attracted much attention as a potential therapeutic target due to its central role in many oncogenic signaling pathways, its frequent dysregulation in cancers and neurological disorders, and its tractability as a target for smallmolecule inhibition. To date, several PAK1-targeting compounds have been developed as preclinical agents, including one that has been evaluated in a clinical trial. A series of ATP-competitive inhibitors, allosteric inhibitors and peptide inhibitors with distinct biochemical and pharmacokinetic properties represent useful laboratory tools for studies on the role of PAK1 in biology and in disease contexts, and could lead to promising therapeutic agents. Given the central role of PAK1 in vital signaling pathways, future clinical development of PAK1 inhibitors will require careful investigation of their safety and efficacy.

Original languageEnglish
Pages (from-to)79-88
Number of pages10
JournalBiochemical Society Transactions
Volume45
Issue number1
DOIs
StatePublished - Feb 8 2017

Fingerprint

Dive into the research topics of 'Targeting PAK1'. Together they form a unique fingerprint.

Cite this